CoChat

SL651498, a GABAAReceptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms

Open access
Griebel, Guy, Perrault, Ghislaine, Simiand, Jacques, Cohen, Caroline, Granger, Patrick, Depoortere, Henri, Françon, Dominique, Avenet, Patrick, Schoemaker, Hans, Evanno, Yannick, Sevrin, Mireille, George, Pascal, Scatton, Bernard · 2003 · CNS Drug Reviews
Cited by 76

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

SL651498 (6‐fluoro‐9‐methyl‐2‐phenyl‐4‐(pyrrolidin‐1‐yl‐carbonyl)‐2, 9‐dihydro‐1 H‐pyrido[3,4‐b]indol‐1‐one) was identified as a drug development candidate from a research program designed to discover subtype‐selective GABA A receptor agonists for the treatment of generalized anxiety disorder and muscle spasms. The drug displays high affinity for rat native GABA A receptors containing α 1(Ki= 6.8 nM) and α 2(Ki= 12.3 nM) subunits, and weaker affinity for α 5‐containing GABA A receptors (Ki= 117 nM). Studies on recombinant rat GABA A receptors confirm these findings and indicate intermediate affinity for the α 3 β 2 γ 2 subtype. SL651498 behaves as a full agonist at recombinant rat GABA A receptors containing α 2 and α 3 subunits, and as a partial agonist at recombinant GABA A receptors expressing α 1 and α 5 subunits. SL651498 produced anxiolytic‐like and skeletal muscle relaxant effects qualitatively similar to those of benzodiazepines (BZs) [minimal effective dose (MED): 1 to 10 mg/kg, i.p. and 3 to 10 mg/kg, p.o.]. However, unlike these latter drugs, SL651498 induced muscle weakness, ataxia or sedation at doses much higher than those having anxiolytic‐like activity (MED: 30 to 100 mg /kg, i.p. or p.o.). Moreover, in contrast to BZs, SL651498 did not produce tolerance to its anticonvulsant activity or physical dependence. It was much less active than BZs in potentiating the depressant effects of ethanol or impairing cognitive processes in rodents. The differential profile of SL651498 as compared to BZs may be related to its selective efficacy at the α 2 and α 3‐containing GABA A receptors. This suggests that selectively targeting GABA A receptor subtypes can lead to drugs with increased clinical specificity. SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1527-3458.2003.tb00241.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 76

Metadata

Authors
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Depoortere, H., Françon, D., Avenet, P., Schoemaker, H., Evanno, Y., Sevrin, M., George, P., & Scatton, B.
Venue
CNS Drug Reviews
Publisher
Wiley
Published
2003-03
Volume
9
Issue
1
Pages
3-20
ISSN
  • 1080-563X (ISSN-L)
  • 1527-3458
OpenAlex
W1971227264
Cited by
76
References
8
FWCI
1.78
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SL651498, a GABAAReceptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms. https://app.cochat.ai/papers/10.1111/j.1527-3458.2003.tb00241.x
The paper
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Depoortere, H., Françon, D., Avenet, P., Schoemaker, H., Evanno, Y., Sevrin, M., George, P., & Scatton, B. (2003). SL651498, a GABAAReceptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2003.tb00241.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.